ResearcherBeaumont HospitalActive in the last 2 years

Bryan T. Hennessy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7871-6477; OpenAlex author ID A5004102701. Sources: ClinicalTrials.gov.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 1 (principal investigator on 1)
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 trial · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 1

Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemcitabine and NAB-paclitaxel therapy in adv… Last author DOI 10.1186/s12885-025-14512-2 ↗

Trials 1

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Principal investigator NCT04617067 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

David J. Easty · 1 shared paper, 2026 · strength 0.23
- Paper Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemci… DOI 10.1186/s12885-025-14512-2 ↗
Derek Gerard Power · 1 shared paper, 2026 · strength 0.23
- Paper Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemci… DOI 10.1186/s12885-025-14512-2 ↗
Patrick Glyn Morris · 1 shared paper, 2026 · strength 0.23
- Paper Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemci… DOI 10.1186/s12885-025-14512-2 ↗
Ray McDermott · 1 shared paper, 2026 · strength 0.23
- Paper Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemci… DOI 10.1186/s12885-025-14512-2 ↗
Adrian Gerard Murphy · 1 shared paper, 2026 · strength 0.23
- Paper Early termination of NCT04617067, a phase II, open label, clinical trial of oral paricalcitol in combination with gemci… DOI 10.1186/s12885-025-14512-2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.